Phase 3 N=6 Safety and Efficacy of Fluoxetine in Juvenile Fibromyalgia
Juvenile Primary Fibromyalgia Syndrome (JPFS) · Fibromyalgia
Primary: Average Pain Severity Score — 62 mm
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=114 Coping Skills Training for Adolescents With Fibromyalgia
Fibromyalgia
Primary: Change in FDI (Functional Disability Inventory) Scores at End of Study — 21.4; 19.2; 13.4; 17.0 units on a 0-60 scale — p=0.007
N/A N=317 Fibromyalgia Integrative Training for Adolescents With Juvenile Fibromyalgia
Fibromyalgia · Myofascial Pain Syndrome · Muscular Diseases
Primary: Functional Disability Inventory — 25.78; 24.10; 25.96; 21.83 score on a scale
Phase 3 N=184 A Study of Duloxetine in Adolescents With Juvenile Primary Fibromyalgia Syndrome
Fibromyalgia
Primary: Change From Baseline to 13 Week Endpoint in Brief Pain Inventory (BPI) Modified Short Form-adolescent Version 24 Hour Average Pain Severity Item — -1.62; -0.97 units on…
N/A N=40 Fibromyalgia Integrative Training for Teens
Juvenile Fibromyalgia
Primary: Average Pain Intensity — 6.26; 6.41; 4.69; 6.38 units on a scale — p=.011
Phase 4 N=107 Adolescent Fibromyalgia Study
Fibromyalgia
Primary: Change From Baseline to Week 15 in Mean Pain Diary Score — -1.60; -0.94 Units on a scale — p=0.121
Phase 3 N=289 Efficacy of Web-based Pain Self-management for Adolescents With Juvenile Idiopathic Arthritis
Juvenile Idiopathic Arthritis
Primary: Change in Pain Intensity — 3.56; 3.26; 3.07; 2.90 Units on a scale — p=<.001
N/A N=23 Jointstrong Intervention for Juvenile Arthritis
Juvenile Arthritis
Primary: Pain — 4.3; 5.7 units on a scale
Phase 2 N=71 Safety and Effectiveness of Rilonacept for Treating Systemic Juvenile Idiopathic Arthritis in Children and Young Adults
Juvenile Idiopathic Arthritis
Primary: Time to Response to Treatment, as Determined by a Modified JIA ACR30 Requiring no Fever, Coupled With a Requirement for Corticosteroid Taper in Participants Who Are…
N/A N=100 Sleep Shared-Management Intervention for Children With Juvenile Idiopathic Arthritis
Juvenile Idiopathic Arthritis
Primary: Sleep Disturbance — 62.1; 62.4; 57.7; 58.3 T-score
Phase 4 N=63 Pregabalin In Adolescent Patients With Fibromyalgia
Fibromyalgia
Primary: Change From Baseline in Pain Numeric Rating Scale by Week — 6.7; -2.1; -1.8; -2.1 Number
Phase 4 N=12 Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis
Juvenile Idiopathic Arthritis
Primary: Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs) — 12; 7; 5; 0 participants
Phase 3 N=190 BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis
Juvenile Rheumatoid Arthritis
Primary: Time to Occurrence of Juvenile Rheumatoid Arthritis/Juvenile Idiopathic Arthritis (JRA/JIA) Disease Flare During Double-Blind Phase (Period B) — NA; 6 months — p=0.0002
Phase 4 N=58 Drug and Talk Therapy for Fibromyalgia
Fibromyalgia
Primary: Change in Weekly Average Pain Intensity — -2.1; -0.97; -1.67 units on a scale
Phase 4 N=85 Trial of Early Aggressive Drug Therapy in Juvenile Idiopathic Arthritis
Juvenile Chronic Polyarthritis · Juvenile Idiopathic Arthritis · Juvenile Rheumatoid Arthritis
Primary: Proportion of Participants Who Attain Inactive Disease by 6 Months — 10; 17 participants
Phase 3 N=32 Active Juvenile Idiopathic Arthritis (JIA) Compassionate Use
Juvenile Idiopathic Arthritis
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 29; 5 participants
N/A N=16 Sleep Innovations for Preschoolers With Arthritis (SIPA): Developing and Pilot Testing of a Self-Management Intervention
Juvenile Idiopathic Arthritis
Primary: Feasibility as Assessed by Adherence — 12 Participants
N/A N=66 Tai Chi Mind-Body Therapy for Fibromyalgia
Fibromyalgia
Primary: Mean Change From Baseline of Fibromyalgia Impact Questionnaire Score — -27.8; -9.4 units on a scale
Phase 3 N=133 Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA)
Arthritis, Juvenile Idiopathic
Primary: Number of Subjects in the Non-MTX Stratum With Disease Flare During the Double-Blind Phase — 13; 20 Participants — p=0.031
Phase 1 N=26 Pharmacokinetics Of CP-690,550 In Pediatric Patients With Juvenile Idiopathic Arthritis (JIA)
Juvenile Idiopathic Arthritis
Primary: Apparent Oral Clearance (CL/F) — 28.09; 25.48; 20.53 liter per hour
Phase 4 N=10 Abatacept in Juvenile Dermatomyositis
Dermatomyositis
Primary: Number of Patients Meeting the Definition of Improvement (DOI) at Week 24: at Least 3 of 6 Core Set Measures (CSM) Improved by ≥ 20% With no More Than 2 CSM Worsening by…
Phase 4 N=308 A Study for Adult Patients With Fibromyalgia
Fibromyalgia, Primary · Fibromyalgia, Secondary
Primary: Change From Baseline to 12-Week Endpoint in the Brief Pain Inventory (BPI) "24-Hour Average Pain" Item (Question 3) of the BPI-Modified Short Form Score — -2.04; -1.70…
N/A N=9 Virtual Reality and Meditation for Fibromyalgia
Fibromyalgia
Primary: Pain Numerical Rating Scale [NRS] (Change From Pre-intervention to Post-intervention) — 4.4; 4.8 score on a scale
Phase 2 N=56 Neurotropin Treatment of Fibromyalgia
Fibromyalgia
Primary: Fibromyalgia Impact Questionnaire — 49.9; 37.5; 39.9; 33.4 units on a scale
N/A N=46 Internet Self-Management Program With Telephone Support for Adolescents With Arthritis
Juvenile Idiopathic Arthritis
Primary: Juvenile Arthritis Quality of Life Questionnaire (JAQQ) — 2.35; 2.74; 1.95; 2.27 units on a scale
N/A N=43 Transcutaneous Electrical Nerve Stimulation (TENS) and Fibromyalgia (FM)
Fibromyalgia
Primary: Pain at Rest Difference Score Pre-intervention and Post Intervention — 0.38; -0.74; -0.47 units on a scale
Phase 3 N=193 Pediatric Arthritis Study of Certolizumab Pegol
Polyarticular-course Juvenile Idiopathic Arthritis (JIA)
Primary: Certolizumab Pegol (CZP) Plasma Concentration Level at Week 16 — 1.6166; 9.2277; 13.8928; 22.9060 ug/ml
Phase 3 N=188 A Study of Tocilizumab in Patients With Active Polyarticular Juvenile Idiopathic Arthritis
Juvenile Idiopathic Arthritis
Primary: Percent of Patients With a Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology 30 (ACR30) Flare in Part II of the Study (Weeks 16-40) — 48.1; 25.6…
Phase 3 N=548 A Safety and Efficacy Study of Xyrem® in Subjects With Fibromyalgia
Fibromyalgia
Primary: Pain VAS (Visual Analog Scale) Response. Percentage of Subjects With a Greater Than or Equal to 30% Reduction in Pain VAS From Baseline (BOCF). — 27.3; 46.2; 39.3; 72.7…
N/A N=84 Lifestyle Physical Activity to Reduce Pain and Fatigue in Adults With Fibromyalgia
Fibromyalgia
Primary: Ambulatory Pain (Higher Values Indicate Greater Pain) — 54.6; 58.9; 46.3; 62.4 units on a scale